Latest Innovation News

Singular Health has landed a pivotal $2 million US pilot contract with Provider Network Solutions and completed an $8 million capital raise, advancing its medical imaging platform’s regulatory and product development milestones.

Mandrake Resources reports progress on its Utah Lithium Project, highlighting a 3.3Mt inferred lithium resource and new brine flow modelling to target high-grade zones. The company maintains a strong cash position while exploring strategic growth opportunities.

Oneview Healthcare reported a €4 million cash outflow in Q2 2025, driven by restructuring and lower R&D credits, while securing new US hospital contracts and expanding AI-powered care solutions.

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

icetana Limited reports its strongest quarterly annual recurring revenue growth in over four years, boosted by a landmark $3.6 million strategic partnership with SoftBank Robotics Group and expanding global deployments.

Lloyds Banking Group reported a robust first half in 2025, with net income up 6%, strong lending growth, and a 15% increase in its interim dividend. The bank reaffirmed its 2025 guidance and expressed confidence in meeting ambitious 2026 targets.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

Universal Biosensors reports a $1.59 million improvement in operating cash outflows for Q2 2025, maintaining $2.55 million in cash as it advances commercialization across blood, wine, and water testing markets.

DroneShield Limited has secured a $5 million contract under Australia’s Project LAND156 to supply portable counter-drone systems to the Australian Defence Force, positioning itself as a key player in the nation’s evolving defence technology landscape.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Alterity Therapeutics has published a peer-reviewed study introducing the MSA Atrophy Index, a novel MRI-based biomarker that enhances diagnosis and monitoring of Multiple System Atrophy, potentially transforming clinical trials and patient care.

Althea Group Holdings announces the immediate resignation of founder and CEO Joshua Fegan, appointing Barry Katzman as interim CEO to steer the company’s THC beverage growth in North America.